Investing.com -- Shares of Cytokinetics (NASDAQ: NASDAQ: CYTK) climbed 11% after Edgewise Therapeutics reported results for its treatment of hypertrophic cardiomyopathy (HCM), which led to a 28% ...
On March 17, analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics, Incorporated (NASDAQ:CYTK ...
Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” ...
Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...
H.C. Wainwright reaffirmed its Buy rating for Cytokinetics with a price target of $120.00, highlighting new analyses of aficamten’s effects when used with standard care therapy and its long-term ...
The market movement reflects investor sentiment on the potential implications for Cytokinetics’ own HCM treatment, aficamten. Morgan Stanley analyst Maxwell Skor maintained an Overweight rating ...
Cytokinetics, Incorporated’s CYTK share price has surged by 13.20%, which has investors questioning if this is right time to ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Cytokinetics (CYTK) stock rises and rival Edgewise (EWTX) stock drops as the latter posts mixed Phase 2 trial data for its ...
Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback